Prelude TherapeuticsPRLD -4.29%26 Debt-to-Equity is 0.29 as of Mar. 2026, which is 2800% above its 10-year median of 0.01. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 964 Biotechnology companies, Prelude Therapeutics ranks worse than 63.07% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Prelude Therapeutics's Debt-to-Equity or its related term are showing as below:
PRLD'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01 Med: 0.01 Max: 0.31
Current: 0.29
During the past 8 years, the highest Debt-to-Equity Ratio of Prelude Therapeutics was 0.31. The lowest was -0.01. And the median was 0.01.
PRLD's Debt-to-Equity is ranked worse than 63.07% of 964
companies
in the Biotechnology industry
Industry Median: 0.16
vs PRLD: 0.29
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Prelude Therapeutics Debt-to-Equity Related Terms
Prelude Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Prelude Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRLD vs DMAC, RCKT, CYDY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Prelude Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prelude Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Prelude Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prelude Therapeutics (PRLD) has a Debt-to-Equity of 0.29 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Prelude Therapeutics and its competitors. This is 2800% above median its historical median of 0.01. According to the industry distribution chart, Prelude Therapeutics ranks #608 out of 964 companies in the Biotechnology industry, placing it in the top 63.1%.
Is Prelude Therapeutics' Debt-to-Equity too high?
Prelude Therapeutics' current Debt-to-Equity of 0.29 is 2800% above median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. Prelude Therapeutics' value of 0.29 is 81.3% above this industry median. Based on the distribution chart, Prelude Therapeutics ranks #608 out of 964 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' Debt-to-Equity compare to DMAC and RCKT?
According to the Biotechnology industry distribution chart, Prelude Therapeutics ranks #608 out of 964 companies for Debt-to-Equity. This places Prelude Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Prelude Therapeutics' value of 0.29 is 81.3% above this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.16, Prelude Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prelude Therapeutics's current Debt-to-Equity of 0.29 is 81.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Prelude Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prelude Therapeutics's current Debt-to-Equity is 0.29, which is 2800% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current Debt-to-Equity of 0.29. The current Debt-to-Equity is 0.29, which is 2800% above median its 10-year median of 0.01 and 81.3% above the Biotechnology industry median of 0.16. Prelude Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current Debt-to-Equity is 0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score
Get the complete analysis for PRLD
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRLD has been successfully added to your 
